amiodaron
adiethylaminoethoxybenzoyl
benzofuran
amd
class
iii
antiarrhythm
drug
known
caus
idiosyncrat
hepatotox
reaction
human
patient
one
hypothesi
etiolog
idiosyncrat
advers
drug
reaction
concurr
inflammatori
stress
result
decreas
threshold
drug
toxic
explor
hypothesi
anim
model
male
spraguedawley
rat
treat
nonhepatotox
dose
amd
vehicl
salin
vehicl
lipopolysaccharid
lp
induc
lowlevel
inflamm
elev
alanin
aminotransferas
alt
aspart
aminotransferas
alkalin
phosphatas
gammaglutamyltransferas
activ
well
increas
total
bile
acid
concentr
serum
midzon
hepatocellular
necrosi
observ
amdlpscotr
rat
time
interv
amd
lp
administr
critic
amd
inject
h
lp
led
liver
injuri
wherea
amd
inject
h
lp
fail
caus
respons
increas
alt
activ
amdlp
cotreat
show
clear
doserespons
relationship
amd
well
lp
metabol
hepat
accumul
amd
affect
lp
coexposur
serum
concentr
tumor
necrosi
factoralpha
tnf
significantli
increas
lp
slightli
prolong
amd
cell
addit
tnf
potenti
cytotox
amd
primari
metabolit
monondesethylamiodaron
vivo
inhibit
tnf
signal
etanercept
attenu
amdlpsinduc
liver
injuri
rat
summari
amd
treatment
modest
inflamm
induc
sever
hepatotox
rat
tnf
contribut
induct
liver
injuri
anim
model
idiosyncrat
amdinduc
liver
injuri
amiodaron
adiethylaminoethoxybenzoyl
benzofuran
amd
class
iii
antiarrhythm
drug
known
caus
idiosyncrat
hepatotox
reaction
human
patient
one
hypothesi
etiolog
idiosyncrat
advers
drug
reaction
concurr
inflammatori
stress
result
decreas
threshold
drug
toxic
explor
hypothesi
anim
model
male
spraguedawley
rat
treat
nonhepatotox
dose
amd
vehicl
salin
vehicl
lipopolysaccharid
lp
induc
lowlevel
inflamm
elev
alanin
aminotransferas
alt
aspart
aminotransferas
alkalin
phosphatas
gammaglutamyltransferas
activ
well
increas
total
bile
acid
concentr
serum
midzon
hepatocellular
necrosi
observ
amdlpscotr
rat
time
interv
amd
lp
administr
critic
amd
inject
h
lp
led
liver
injuri
wherea
amd
inject
h
lp
fail
caus
respons
increas
alt
activ
amdlp
cotreat
show
clear
doserespons
relationship
amd
well
lp
metabol
hepat
accumul
amd
affect
lp
coexposur
serum
concentr
tumor
necrosi
factoralpha
tnf
significantli
increas
lp
slightli
prolong
amd
cell
addit
tnf
potenti
cytotox
amd
primari
metabolit
monondesethylamiodaron
vivo
inhibit
tnf
signal
etanercept
attenu
amdlpsinduc
liver
injuri
rat
summari
amd
treatment
modest
inflamm
induc
sever
hepatotox
rat
tnf
contribut
induct
liver
injuri
anim
model
idiosyncrat
amdinduc
liver
injuri
key
word
amiodaron
hepatotox
inflamm
lipopolysaccharid
idiosyncrat
advers
drug
reaction
drug
metabol
tumor
necrosi
factoralpha
idiosyncrat
advers
drug
reaction
iadr
typic
occur
small
fraction
patient
treat
certain
drug
therapeut
dose
iadr
usual
unrel
pharmacolog
target
drug
present
seriou
human
health
problem
usual
predict
current
preclin
safeti
evalu
drug
develop
period
newli
approv
drug
withdrawn
us
market
receiv
black
box
warn
due
advers
reaction
uetrecht
mechan
iadr
occur
clear
evid
experiment
anim
indic
mild
inflamm
decreas
threshold
toxic
therebi
render
individu
suscept
advers
drug
reaction
would
otherwis
occur
lipopolysaccharid
lp
cell
wall
compon
gramneg
bacteria
wide
use
inflammagen
anim
studi
nonhepatotox
dose
lp
interact
nontox
dose
sever
iadrassoci
drug
differ
pharmacolog
class
induc
liver
damag
rodent
deng
et
al
luyendyk
et
al
ware
et
al
zou
et
al
amiodaron
adiethylaminoethoxybenzoyl
benzofuran
amd
class
iii
antiarrhythm
drug
effect
increas
surviv
patient
myocardi
infarct
congest
heart
failur
singh
sinc
approv
amd
us
food
drug
administr
use
drug
associ
varieti
advers
effect
includ
liver
dysfunct
pulmonari
complic
thyroid
dysfunct
ocular
disturb
rotmensch
et
al
report
frequenc
liver
abnorm
patient
receiv
amd
vari
lewi
et
al
reaction
mild
serum
transaminas
elev
within
threefold
upper
limit
normal
uln
sever
babatin
et
al
case
liver
reaction
intraven
administr
amd
rare
damag
acut
mark
bravo
et
al
fulmin
hepat
failur
death
associ
amd
hepatotox
also
report
babatin
et
al
evid
interact
lpsinduc
cytokin
drug
metabolit
play
import
role
lpsdrug
interact
zou
et
al
tumor
necrosi
factoralpha
tnf
proxim
mediat
inflammatori
cascad
induc
lp
beutler
kruy
critic
involv
mani
model
liver
injuri
ischemiareperfus
teoh
et
al
alcohol
liver
diseas
yin
et
al
druglpsinduc
liver
injuri
model
shaw
et
al
tukov
et
al
zou
et
al
exampl
tnf
select
augment
cytotox
sulindac
sulfid
major
toxic
metabolit
sulindac
zou
et
al
case
amiodaron
major
metabolit
amd
monondesethylamiodaron
dea
share
similar
pharmacolog
talaj
et
al
pharmacokinet
shayeganpour
et
al
characterist
amd
dea
antiarrhythm
properti
long
halflif
accumul
liver
mani
tissu
primari
hepatocyt
cell
cell
type
dea
much
cytotox
amd
waldhaus
et
al
plasma
concentr
dea
greater
case
amdassoci
iadr
osullivan
et
al
suggest
possibl
role
metabolit
amd
toxic
purpos
studi
test
hypothesi
inflammatori
stress
induc
lp
potenti
amiodaroneinduc
hepatotox
rat
result
demonstr
hepatotox
interact
inflammatori
stress
amiodaron
role
metabol
tnf
explor
materi
unless
otherwis
note
chemic
purchas
sigmaaldrich
st
loui
mo
activ
lp
lot
deriv
escherichia
coli
serotyp
endotoxin
unit
eu
mg
determin
limulu
amebocyt
lysat
kineticqcl
kit
cambrex
corp
kit
east
rutherford
nj
reagent
measur
alanin
aminotransferas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
alp
gammaglutamyltransferas
ggt
activ
purchas
thermo
electron
corp
waltham
kit
total
bile
acid
measur
purchas
diazym
laboratori
poway
ca
anim
male
spraguedawley
rat
crl
cd
sd
ig
br
charl
river
portag
mi
weigh
g
use
vivo
studi
fed
standard
chow
rodent
chowtek
harlan
teklad
madison
wi
allow
access
water
ad
libitum
anim
allow
acclim
week
lightdark
cycl
prior
experi
receiv
human
care
accord
criteria
guid
care
use
laboratori
anim
experiment
protocol
experi
rat
fast
h
administr
lp
food
return
thereaft
mgml
solut
amd
made
vehicl
tween
euml
solut
lp
made
steril
salin
determin
optim
time
interv
amd
lp
treatment
rat
treat
amd
mgkg
ip
h
h
h
h
h
lp
eukg
iv
evalu
doserespons
relationship
amd
rat
treat
amd
mgkg
ip
h
later
lp
eukg
iv
salin
evalu
doserespons
relationship
lp
rat
treat
amd
mgkg
ip
vehicl
h
later
lp
eukg
iv
subsequ
studi
rat
treat
amd
mgkg
ip
vehicl
h
later
lp
eukg
iv
salin
etanercept
treatment
studi
rat
treat
etanercept
mgkg
steril
water
sc
inject
h
lp
rat
anesthet
isofluran
blood
liver
sampl
taken
serum
prepar
blood
plasma
prepar
blood
collect
syring
contain
sodium
citrat
bd
bioscienc
san
diego
ca
right
medial
lobe
liver
rapidli
frozen
immunohistochemistri
left
later
lobe
liver
fix
neutralbuff
formalin
store
ethanol
histopatholog
evalu
liver
injuri
liver
injuri
estim
serum
activ
alt
ast
alp
ggt
serum
concentr
total
bile
acid
formalinfix
liver
sampl
embed
paraffin
section
stain
hematoxylin
eosin
h
e
stain
stain
liver
section
examin
use
light
microscopi
drug
metabolit
analysi
serum
sampl
liver
homogen
mix
acetonitril
contain
ethopropazin
intern
standard
vortex
centrifug
protein
remov
supernat
dilut
transfer
autosampl
vial
liquid
chromatographytandem
mass
spectrometri
lcmsm
analysi
lcmsm
analysi
perform
use
shimadzu
high
perform
liquid
chromatographi
hplc
system
coupl
qtrap
tandem
quadrupol
mass
spectromet
ab
sciex
foster
citi
ca
oper
control
analyst
v
softwar
ascenti
express
hplc
column
cm
mm
lm
maintain
volum
inject
hplc
system
elut
gradient
base
ammonium
acet
h
solvent
methanol
solvent
b
min
solvent
b
min
solvent
b
min
solvent
b
min
solvent
b
flow
rate
mlmin
posit
mode
electrospray
ioniz
use
analys
mass
spectrometri
paramet
includ
declust
potenti
collis
energi
optim
independ
analyt
multipl
reaction
monitor
mz
transit
use
quantit
analysi
amd
mz
dea
mz
ethopropazin
mz
lcmsm
method
achiev
lower
limit
quantif
ngml
amd
ngml
dea
analyt
reproduc
judg
middl
calibr
rang
concentr
pierc
bca
protein
assay
kit
thermo
scientif
rockford
il
use
determin
protein
concentr
liver
homogen
assess
cytotox
vitro
murin
hepatoma
cell
line
purchas
american
type
cultur
collect
manassa
va
use
assess
cytotox
vitro
cell
maintain
dulbecco
modifi
eagl
medium
invitrogen
carlsbad
ca
antibioticantimycot
invitrogen
heatinactiv
fetal
bovin
serum
safc
bioscienc
lenexa
ks
tissu
cultur
flask
humidifi
atmospher
air
co
cell
plate
plate
cell
per
well
allow
attach
h
medium
replac
variou
concentr
amd
dea
andor
tnf
ad
design
well
cell
incub
mainten
condit
twentyfour
hour
later
lactat
dehydrogenas
ldh
activ
releas
cultur
medium
measur
use
cytotoxon
homogen
membran
integr
assay
promega
madison
wi
percent
ldh
releas
calcul
ldh
supernat
ldh
supernat
ldh
cell
lysat
lysat
ldh
determin
addit
triton
lyse
cell
statist
analysi
result
express
mean
sem
oneway
twoway
anova
appli
appropri
tukey
method
employ
post
hoc
test
grubb
test
use
detect
outlier
least
three
biolog
repetit
perform
experi
p
valu
set
criterion
statist
signific
serum
alt
activ
increas
treatment
either
lp
amd
alon
fig
amdlp
group
administr
amd
h
lp
result
signific
serum
alt
activ
increas
wherea
amd
inject
h
lp
fail
caus
respons
interv
amd
lp
treatment
select
futur
studi
neither
amd
alon
lp
alon
affect
alt
activ
dose
test
rat
cotreat
amd
lp
serum
alt
activ
depend
amd
fig
lp
fig
dose
signific
increas
alt
activ
observ
amd
dose
mgkg
p
lp
dose
eukg
p
mgkg
eukg
select
amd
lp
dose
subsequ
studi
respect
time
cours
studi
serum
activ
alt
ast
measur
marker
hepatocellular
injuri
fig
b
neither
amd
lp
alon
affect
serum
alt
activ
time
examin
ast
activ
lp
alon
effect
time
examin
amd
alon
caus
slight
increas
h
signific
elev
serum
alt
ast
activ
observ
amd
lp
cotreat
increas
start
h
lp
administr
continu
increas
h
h
lp
administr
serum
activ
alp
ggt
concentr
bile
acid
measur
indic
cholestat
injuri
fig
amdlp
cotreat
caus
signific
increas
serum
marker
wherea
amd
lp
treatment
alon
effect
salinetr
control
rat
free
liver
lesion
fig
microscop
evid
hepat
patholog
found
four
six
lpstreat
rat
fig
liver
section
two
lpstreat
rat
small
foci
midzon
hepatocellular
necrosi
associ
neutrophil
influx
contrast
widespread
mildtomark
fibrinopurul
capsul
present
liver
section
amdtreat
rat
fig
character
thicken
hepat
capsul
due
edema
conspicu
inflammatori
exud
compris
mainli
neutrophil
lesser
number
mononuculear
cell
variou
amount
amorphor
proteinac
materi
fibrinopurul
exud
also
often
scatter
along
outer
periton
surfac
capsul
focal
area
subcapular
hepatocellular
necrosi
occasion
associ
capsul
profound
hepat
histopatholog
found
anim
treat
amd
lp
fig
rat
mildtomark
fibrinopurul
capsul
occasion
subcapsular
necrosi
similar
found
amdtreat
rat
addit
anim
conspicu
area
midzon
hepatocellular
necrosi
latter
lesion
rang
wide
scatter
focal
area
necrosi
midzon
region
widespread
hepatocellular
necrosi
coalesc
affect
midzon
occasion
centriacinar
region
bridg
necrosi
accumul
neutrophil
inset
fig
present
necrot
region
periport
region
spare
amdlp
treatmentrel
injuri
rat
treat
amd
mgkg
ip
h
later
salin
lp
eukg
iv
b
rat
treat
amd
mgkg
ip
vehicl
h
later
lp
eukg
iv
serum
alt
activ
measur
h
lp
administr
data
set
indic
significantli
differ
respect
group
given
lp
indic
significantli
differ
respect
group
given
amd
p
n
accumul
amd
amd
dea
concentr
rat
serum
liver
homogen
determin
variou
time
lp
administr
fig
h
lp
salin
administr
ie
h
amd
administr
serum
tissu
concentr
amd
dea
unaffect
lp
cotreat
averag
serum
concentr
amd
dea
ngml
respect
averag
liver
concentr
amd
dea
ngmg
protein
respect
serum
tnf
concentr
measur
h
lp
administr
fig
amd
effect
serum
tnf
concentr
h
lp
serum
tnf
concentr
rat
treat
amdlp
vehicl
lp
similar
howev
h
lp
concentr
tnf
serum
amdlpstreat
rat
significantli
greater
vehiclelpstr
rat
cell
expos
amd
dea
h
later
cytotox
assess
measur
ldh
activ
releas
cultur
medium
fig
b
amd
dea
caus
concentrationdepend
ldh
releas
signific
cytotox
observ
amd
concentr
greater
ugml
dea
concentr
greater
ugml
addit
tnf
ngml
caus
cytotox
alon
significantli
potenti
cytotox
amd
dea
etanercept
solubl
tnf
receptor
construct
inactiv
tnf
etanercept
mgkg
sc
inject
h
lp
inhibit
biolog
activ
tnf
rat
hepatotox
tukov
et
al
zou
et
al
treatment
use
studi
amdlp
cotreat
increas
serum
alt
activ
etanercept
significantli
attenu
increas
fig
chang
serum
alt
activ
support
histolog
rat
treat
amd
mgkg
ip
vehicl
h
later
lp
eukg
iv
salin
examin
h
lp
inject
activ
alt
b
ast
serum
measur
indic
significantli
differ
respect
group
given
lp
indic
significantli
differ
respect
group
given
amd
p
n
amd
hepatotox
modest
inflamm
examin
h
estain
liver
section
sever
frequenc
necrot
foci
markedli
reduc
rat
cotreat
etanercept
fig
sinc
introduct
europ
amiodaron
associ
idiosyncrat
hepatotox
lewi
et
al
linear
correl
serum
amd
concentr
serum
alt
activ
establish
pollak
howev
studi
alt
valu
exceed
uln
consid
clinic
signific
case
sever
liver
injuri
caus
intraven
amiodaron
load
patient
serum
alt
activ
uln
usual
h
delay
initi
load
amd
onset
elev
alt
activ
mani
case
alt
activ
return
normal
day
continu
mainten
dose
bravo
et
al
accordingli
hard
draw
simpl
linear
relationship
magnitud
frequenc
sever
hepatotox
serum
amd
concentr
effort
establish
model
amdinduc
liver
injuri
healthi
rodent
unsuccess
neither
shortterm
larg
dose
longterm
small
dose
administr
amd
led
observ
liver
damag
young
mehendal
caus
sever
amd
hepatotox
like
combin
amd
factor
eg
inflammatori
variou
concentr
amd
b
dea
ad
cultur
cell
togeth
tnf
ngml
salin
twentyfour
hour
treatment
ldh
activ
releas
cultur
medium
measur
percent
ldh
releas
calcul
describ
materi
method
section
indic
significantli
differ
respect
group
given
tnf
indic
significantli
differ
respect
group
given
amd
dea
p
n
episod
present
studi
regardless
cotreat
lp
serum
concentr
amd
ngml
close
steadyst
serum
concentr
amd
human
patient
ngml
longterm
oral
amiodaron
therapi
pollak
et
al
find
support
clinic
relev
concentr
amd
serum
hepatotox
induc
concurr
inflammatori
episod
relat
lp
exposur
previou
studi
rodent
suggest
possibl
associ
inflamm
liver
injuri
sever
drug
associ
human
iadr
includ
chlorpromazin
buchweitz
et
al
ranitidin
diclofenac
deng
et
al
trovafloxacin
shaw
et
al
sulindac
zou
et
al
halothan
dugan
et
al
result
present
studi
expand
find
demonstr
nonhepatotox
dose
amd
render
hepatotox
acut
inflamm
trigger
lp
administr
acut
increas
serum
marker
hepatocellular
cholestat
injuri
found
rat
cotreat
amdlp
resembl
clinic
hepat
chemistri
chang
human
idiosyncrasi
amd
therapi
bravo
et
al
midzon
bridg
necrosi
infiltr
inflammatori
cell
amdlp
also
consist
histolog
chang
found
human
patient
babatin
et
al
bravo
et
al
howev
histolog
characterist
peopl
amdinduc
liver
injuri
variabl
differ
pattern
hepatocellular
necrosi
midzon
centrilobular
bridg
panlobular
report
lewi
et
al
genet
differ
concurr
medic
even
differ
origin
inflamm
might
account
vari
respons
nevertheless
amdlp
interact
model
rat
mimic
import
aspect
amdinduc
iadr
human
patient
time
amd
lp
dose
model
import
develop
sever
liver
damag
minim
interv
h
requir
amd
lp
interact
induc
liver
injuri
lp
inject
within
h
amd
liver
injuri
observ
absorpt
distribut
metabol
clearanc
well
toxicolog
action
could
contribut
time
requir
elimin
amd
primarili
hepat
metabol
biliari
excret
halflif
plasma
long
day
human
pollak
et
al
accordingli
loss
amd
due
elimin
within
h
minim
amd
dosedepend
effect
respiratori
chain
boxid
mitochondria
fromenti
et
al
b
also
affect
function
lysosom
acid
organel
stadler
et
al
interv
may
requir
amd
distribut
liver
accumul
organel
sensit
hepatocyt
interact
lp
downstream
cytokin
druglp
model
also
depend
tempor
relationship
administr
drug
lp
time
interv
need
maxim
hepatotox
respons
differ
differ
drug
shaw
et
al
zou
et
al
time
interv
requir
might
help
explain
low
frequenc
iadr
human
patient
ie
inflammatori
episod
happen
certain
time
drug
therapi
would
idiosyncrat
hepatotox
occur
rat
amd
deethyl
cytochrom
cyp
liver
elsherbini
et
al
dea
major
metabolit
threeto
fivefold
toxic
amd
cultur
cell
waldhaus
et
al
primari
rat
hepatocyt
gross
et
al
treatment
cell
similar
trend
observ
fig
administr
lp
affect
express
activ
cyp
rat
sewer
et
al
rais
possibl
lp
might
potenti
toxic
amd
increas
metabol
dea
evalu
serum
liver
concentr
amd
dea
measur
lc
msm
averag
serum
concentr
dea
amdtreat
rat
ngml
serum
amd
concentr
ratio
commonli
seen
serum
intraven
load
dose
amd
peopl
ha
et
al
rat
shayeganpour
et
al
neither
serum
liver
concentr
amd
dea
affect
lp
cotreat
suggest
neither
amd
accumul
dea
gener
affect
lp
intratrach
instil
amd
vivo
exposur
alveolar
macrophag
amd
vitro
led
tnf
product
futamura
reinhart
gairola
amd
treatment
also
increas
tnf
product
alveolar
macrophag
lp
stimul
punithavathi
et
al
present
studi
treatment
rat
amd
alon
caus
serum
tnf
elev
increas
concentr
tnf
serum
lpstreat
rat
result
suggest
increas
appear
tnf
amdlpscotr
rat
probabl
addit
effect
rather
amd
appear
potenti
product
diminish
clearanc
tnf
caus
lp
concentr
tnf
serum
increas
rapidli
lpstreat
rat
peak
around
h
return
basal
level
around
h
tukov
et
al
present
studi
concentr
tnf
around
peak
time
ie
h
lpscotreat
rat
affect
amd
tnf
concentr
greater
amdcotr
rat
later
time
h
data
suggest
amd
prolong
elev
tnf
caus
lp
administr
seemingli
small
differ
tnf
concentr
shown
critic
liver
pathogenesi
anoth
druglp
model
liver
injuri
involv
trovafloxacin
shaw
et
al
accordingli
possibl
prolong
lpsinduc
tnf
respons
critic
event
across
model
lpsdrug
interact
import
tnf
amd
model
explor
prevent
bind
cellular
receptor
etanercept
etanercept
pretreat
reduc
hepatotox
indic
tnf
import
role
amdlpsinduc
liver
injuri
liver
injuri
observ
treatment
lp
amd
hepatotox
modest
inflamm
alon
larg
tnf
peak
caus
lp
hepatotox
howev
amount
tnf
could
critic
induct
hepatocellular
injuri
potenti
toxic
effect
amd
andor
dea
signal
activ
tnf
receptor
lead
lysosom
leakag
mitochondri
damag
caspas
activ
wullaert
et
al
three
event
also
found
amd
dea
cytotox
vitro
agoston
et
al
spaniol
et
al
support
critic
role
tnf
came
vitro
studi
cell
tnf
increas
cytotox
amd
dea
proxim
proinflammatori
cytokin
tnf
also
contribut
liver
damag
induc
downstream
inflammatori
event
coagul
activ
neutrophil
activ
shaw
et
al
tukov
et
al
etanercept
treatment
herein
reduc
alt
activ
half
level
seen
absenc
inhibitor
wherea
dose
etanercept
reduc
alt
activ
almost
control
level
trovafloxacinlp
sulindaclp
model
shaw
et
al
zou
et
al
suggest
factor
induc
lp
might
act
parallel
tnf
amdlp
model
model
potenti
xenobiot
toxic
lp
factor
neutrophil
luyendyk
et
al
coagul
system
shaw
et
al
prostanoid
ganey
et
al
play
import
role
factor
might
relev
model
present
summari
amd
render
hepatotox
rat
presenc
coexist
inflammatori
stress
induc
lp
amdlpscotr
rat
develop
liver
patholog
blood
chemistri
chang
resembl
amdinduc
idiosyncrat
hepatotox
human
patient
lp
interact
amd
chang
metabol
distribut
amd
amd
enhanc
increas
plasma
tnf
concentr
caus
lp
neutral
tnf
reduc
liver
injuri
amdlp
coexposur
moreov
tnf
potenti
cytotox
amd
dea
vitro
find
add
support
idea
inflammatori
stress
interact
iadrassoci
drug
caus
liver
injuri
mechan
involv
tnf
suggest
similar
mode
action
might
appli
sever
drug
caus
idiosyncrat
hepatotox
human
nation
institut
health
